Jennifer Cunningham
Family Medicine · Mount Jackson, VANPI 1750469334
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 160 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Novo Nordisk at 24.8% of the total. Reporting peaked in 2024 at $951 and has fallen 67.5% since, to $309 in 2025.
Across 160 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$694
- AstraZeneca$458
- Pfizer$377
- Amgen$340
- Lilly USA, LLC$300
- Johnson & Johnson$165
- plus $469 from 11 others
What the payments were for
- Food & beverage$2,69696%
- Education$1074%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $694 |
| AstraZeneca | 28 | $458 |
| Pfizer | 27 | $377 |
| Amgen | 17 | $340 |
| Lilly USA, LLC | 18 | $300 |
| Johnson & Johnson | 9 | $165 |
| Merck | 6 | $93 |
| EMD Serono, Inc. | 5 | $73 |
| Abbott | 3 | $70 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Boehringer Ingelheim | 2 | $38 |
| Exact Sciences | 1 | $34 |
| Dexcom, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$125
How this compares
$2,803 in reported general payments places this provider in the 80th percentile of 2,553 family medicine providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $70,862 |
| EliquisApixaban | 66 | $56,240 |
| XareltoRivaroxaban | 48 | $50,646 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $39,218 |
| TrulicityDulaglutide | 22 | $31,924 |
| JardianceEmpagliflozin | 15 | $22,793 |
| JanuviaSitagliptin Phosphate | 15 | $22,565 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $12,313 |
| Spiriva RespimatTiotropium Bromide | 16 | $9,404 |
| FarxigaDapagliflozin Propanediol | 12 | $8,671 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 144 | $4,078 |
| Rosuvastatin Calcium | 243 | $2,707 |
| Aripiprazole | 32 | $2,600 |
| Colchicine | 12 | $2,484 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $2,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $694 | $70,86242 claims |
| PfizerEliquis | $377 | $56,24066 claims |
| Johnson & JohnsonXarelto | $165 | $50,64648 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $38 | $32,19731 claims |
| Lilly USA, LLCTrulicity | $300 | $31,92422 claims |
| MerckJanuvia, Janumet | $93 | $24,64727 claims |
| AstraZenecaFarxiga | $458 | $8,67112 claims |
| AbbVieSynthroid | $12 | $1,02234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Mount Jackson
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- Jordan TranWinchester$42K
- John ClayColonial Heights$40K
- Thomas RobesonNewport News$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.